ProMab develops and commercializes recombinant proteins and custom monoclonal antibodies through the integration of bioinformatics, gene cloning, protein expression and purification, and immunology, using novel high-throughput technologies. ProMab applies its proprietary proteins and antibodies to deliver innovative diagnostic products as well as services targeting the global biomedical market through collaborations with other biotechnology and bio-reagent companies.
CAR-T development includes six phases:
Immunization and anti-sera production: $500
Phase I: Amplification, Test expression ($1200)
Phase II: Purification ($600)
Phase I: Subcloning into expression vector - $2000
Phase II: Generation and identification of expression positive clones - $800
ProMab Biotechnologies, Inc. has not received any reviews.
ProMab Biotechnologies, Inc. has not received any endorsements.